Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD - mixed treatment comparisons of clinical efficacy

Respiratory Research

Volumn 16, Issue 1, 2015, Pages

  Stynes, Gillian ^a   Svedsater, Henrik ^a   Wex, Jaro ^a   Lettis, Sally ^a   Leather, David ^a   Castelnuovo, Emanuela ^a   Detry, Michelle ^b   Berry, Scott ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b BERRY CONSULTANTS   (United States)

Author keywords

COPD; Fluticasone furoate; ICS LABA; Mixed treatment comparison; Network meta analysis; Vilanterol

Indexed keywords

BUDESONIDE PLUS FORMOTEROL; FLUTICASONE FUROATE PLUS VILANTEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL; PLACEBO; ANDROSTANE DERIVATIVE; BENZYL ALCOHOL DERIVATIVE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHLOROBENZENE; CORTICOSTEROID; FLUTICASONE FUROATE; FLUTICASONE PROPIONATE PLUS SALMETEROL XINAFOATE; VILANTEROL;

AGE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMBINATION CHEMOTHERAPY; DETERIORATION; DISEASE EXACERBATION; DRUG EFFICACY; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMAN; LUNG FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; ST. GEORGE RESPIRATORY QUESTIONNAIRE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; AGED; BAYES THEOREM; CONVALESCENCE; DISEASE COURSE; DRUG ADMINISTRATION; DRUG EFFECTS; FEMALE; INHALATIONAL DRUG ADMINISTRATION; LUNG; MALE; META ANALYSIS; MIDDLE AGED; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTOR; TIME FACTOR;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; ANDROSTADIENES; BAYES THEOREM; BENZYL ALCOHOLS; BRONCHODILATOR AGENTS; BUDESONIDE, FORMOTEROL FUMARATE DRUG COMBINATION; CHLOROBENZENES; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUTICASONE PROPIONATE, SALMETEROL XINAFOATE DRUG COMBINATION; FORCED EXPIRATORY VOLUME; HUMANS; LUNG; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOVERY OF FUNCTION; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84927710149     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/s12931-015-0184-8     Document Type: Article

References (37)

1. Decramer ML, Hanania NA, Lötvall JO, Yawn BP. The safety of long-acting β2-agonists in the treatment of stable chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2013, 8:53-64. 10.2147/COPD.S39018, 23378756.
2. Dong YH, Lin HH, Shau WY, Wu YC, Chang CH, Lai MS. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials. Thorax 2013, 68:48-56. 10.1136/thoraxjnl-2012-201926, 23042705.
3. Dransfield MT, Feldman G, Korenblat P, LaForce C, Locantore N, Pistolesi M, et al. Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) vs twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients. Respir Med 2014, 108:1171-9. 10.1016/j.rmed.2014.05.008, 24998880.
4. Agusti A, de Teresa L, De Backer W, Zvarich M, Locantore N, Barnes N, et al. A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with fluticasone propionate/salmeterol in COPD patients. Eur Respir J 2014, 43:763-72. 10.1183/09031936.00054213, 24114969.
5. Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, et al. A once-daily inhaled corticosteroid, long-acting beta2-agonist combination, fluticasone furoate (FF)/vilanterol (VI), for the prevention of COPD exacerbations. Lancet Respir Med 2013, 1:210-23. 10.1016/S2213-2600(13)70040-7, 24429127.
6. Kerwin EM, Scott-Wilson C, Sanford L, Rennard S, Agusti A, Barnes N, et al. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD. Respir Med 2013, 107:560-9. 10.1016/j.rmed.2012.12.014, 23352226.
7. Martinez FJ, Boscia J, Feldman G, Scott-Wilson C, Kilbride S, Fabbri L, et al. Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: A randomised trial. Respir Med 2013, 107:550-9. 10.1016/j.rmed.2012.12.016, 23332861.
8. Lötvall J, Bakke P, Bjermer L, Steinshamn S, Crim C, Sanford L, et al. Efficacy and safety of 4 weeks' treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomised trial. BMJ Open 2012, 2:e000370. 10.1136/bmjopen-2011-000370, 22267687.
9. Boscia JA, Pudi KK, Zvarich MT, Sanford L, Siederer SK, Crim C. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with COPD: A randomized, three-way, incomplete block, crossover study. Clin Ther 2012, 34:1655-1666.e5. 10.1016/j.clinthera.2012.06.005, 22789766.
10. Pepin J-L, Cockroft JR, Midwinter D, Sharma D, Rubin DB, Andreas S. Long-acting bronchodilators and arterial stiffness in patients with COPD: a comparison of fluticasone furoate/vilanterol with tiotropium. Chest 2014. doi:10.1378/chest.13-2859 [Epub ahead of print]..
11. Ferguson GT, Anzueto A, Fei R, Emmett A, Knobil K, Kalberg C. Effect of fluticasone propionate/salmeterol (250/50 μg) or salmeterol (50 μg) on COPD exacerbations. Respir Med 2008, 102:1099-108. 10.1016/j.rmed.2008.04.019, 18614347.
12. Kardos P, Wencker M, Glaab T, Vogelmeier C. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 175:144-9. 10.1164/rccm.200602-244OC, 17053207.
13. Fletcher C, Peto R. The natural history of chronic airflow limitation. BMJ 1977, 25:1645-8. 10.1136/bmj.1.6077.1645.
14. Di Stefano A, Capelli A, Lusuardi M, Balbo P, Vecchio C, Maestrelli P. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med 1998, 158:1277-85. 10.1164/ajrccm.158.4.9802078, 9769292.
15. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. Revised 2014. [www.goldcopd.org/uploads/users/files/GOLD_Report_2014.pdf].
16. Tashkin DP, Doherty DE, Kerwin EM, Matiz-Bueno CE, Knorr B, Shekar T, et al. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomised 52-week placebo-controlled trials. Int J Chron Obstruct Pulmon Dis 2012, 7:73-86. 22334770.
17. Donohue JF. Minimal clinically important differences in COPD lung function. COPD 2005, 2:111-24. 10.1081/COPD-200053377, 17136971.
18. Jones P. St. George's Respiratory Questionnaire: MCID. J COPD 2005, 2:75-9. 10.1081/COPD-200050513.
19. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010, 363:1128-38. 10.1056/NEJMoa0909883, 20843247.
20. Smith TC, Spiegelhalter DJ, Thomas A. Bayesian approaches to random-effects meta-analysis: a comparative study. Stat Med 1995, 14:2685-99. 10.1002/sim.4780142408, 8619108.
21. Sutton AJ, Abrams KR. Bayesian methods in meta-analysis and evidence synthesis. Stat Methods Med Res 2001, 10:277-303. 10.1191/096228001678227794, 11491414.
22. Sutton AJ, Higgins JP. Recent developments in meta-analysis. Stat Med 2008, 27:625-50. 10.1002/sim.2934, 17590884.
23. Berry SM, Shane Reese C, Larkey PD. Bridging different eras in sports. J Amer Stat Assoc 1999, 94:661-76. 10.1080/01621459.1999.10474163.
24. Gilks WR, Richardson S, Spiegelhalter D. Markov Chain Monte Carlo in Practice 1996, Chapman & Hall, London.
25. Van Valkenhoef G, Tervonen T, Zwinkels T, de Brock B, Hillege H. ADDIS: A decision support system for evidence-based medicine. Decision Support Systems 2012, 55:459-75. 10.1016/j.dss.2012.10.005.
26. Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS - a Bayesian modelling framework: concepts, structure and extensibility. Stat Comput 2000, 10:325-37. 10.1023/A:1008929526011.
27. Gelman A, Carlin JB, Stern HS, Rubin DB. Bayesian Data Analysis 2003, Chapman & Hall/CRC, London, Second.
28. Food and Drug Administration (FDA): Guidance for Industry: Non-inferiority Clinical Trials. [http://www.fda.gov/downloads/Drugs/.../Guidances/UCM202140.pdf].
29. Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, et al. American Thoracic Society; European Respiratory Society Task Force on outcomes of COPD. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008, 31:416-69. 10.1183/09031936.00099306, 18238951.
30. van Noord JA, Cornelissen PJ, Aumann JL, Platz J, Mueller A, Fogarty C. The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients. Respir Med 2009, 103:22-9. 10.1016/j.rmed.2008.10.002, 19022642.
31. Niewoehner DE, Lapidus R, Cote C, Sharafkhaneh A, Plautz M, Johnson P, et al. Therapeutic conversion of the combination of ipratropium and albuterol to tiotropium in patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2009, 22:587-92. 10.1016/j.pupt.2009.08.006, 19737620.
32. Burge PS, Calverley PMA, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000, 320:1297. 10.1136/bmj.320.7245.1297, 10807619.
33. Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta2-agonist in one inhaler versus long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012, 12. Article ID CD006829.
34. Calverley PMA, Anderson J, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356:775-89. 10.1056/NEJMoa063070, 17314337.
35. Seemungal T, Hurst J, Wedzicha J. Exacerbation rate, health status and mortality in COPD - a review of potential interventions. Int J Chron Obstruct Pulmon Dis 2009, 4:203-23. 10.2147/COPD.S3385, 19554195.
36. Baker WL, Baker EL, Coleman CI. Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed-treatment comparison meta-analysis. Pharmacotherapy 2009, 29:891-905. 10.1592/phco.29.8.891, 19637942.
37. Mills EJ, Druyts E, Ghement I, Puhan MA. Pharmacotherapies for chronic obstructive pulmonary disease: a multiple treatment comparison meta-analysis. Clin Epidemiol 2011, 3:107-29. 10.2147/CLEP.S16235, 21487451.